Board Meeting Outcome for Outcome of Board Meeting for considering and approving Annual Audited Financial Results for the Quarter and Financial Year ended on March 31, 2026
ORCHPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Orchid Pharma reported a 12% revenue decline for FY2026 with standalone net sales falling to Rs. 81,133 lakhs from Rs. 92,193 lakhs in FY2025. Standalone profit after tax dropped 57.5% to Rs. 4,521 lakhs, while consolidated PAT fell 79.4% to Rs. 2,055 lakhs due to losses from associates. The auditors issued an unmodified opinion on standalone results but a qualified opinion on consolidated results because three US subsidiaries' financials were unaudited. Exceptional items of Rs. 53.92 lakhs represent reversal of excess labour code provisions. The company completed acquisitions of Allecra Therapeutics assets in Germany and France, gained full ownership of Enmetazobactam (EXBLIFEP), and set up Orchid Pharma Europe GmbH. An amalgamation with holding company Dhanuka Laboratories is pending NCLT approval.
The sharp revenue and profit decline combined with a qualified audit opinion on consolidated results signals deteriorating financial health. Shareholders should monitor the pending Dhanuka Laboratories amalgamation and the company's ability to restore profitability amid challenging market conditions.